Tempus AI, Recursion extend data license agreement, enter new license agreement
Tempus AI (TEM) and Recursion Pharmaceuticals (RXRX) extended their data license agreement to 2029. They also agreed to a new license for Recursion's RNA Foundation Model. The amended deal replaces potential $84M fees over two years with $42M in committed payments over three years. Recursion granted Tempus a non-exclusive license to its RNA sequencing model, TxFM.
How this was made
The 30-second read
Why it matters
The extension secures future revenue streams for both companies and may set a precedent for similar AI licensing deals in biotech.
Market read
The agreement provides incremental revenue and deepens AI collaboration, modestly bullish for both stocks.
What to watch
Potential regulatory scrutiny of AI models in healthcare and the execution risk of integrating the RNA foundation model.
Background
Tempus AI and Recursion Pharmaceuticals have a multi‑year partnership dating back to 2023, focused on AI models for precision medicine.
Ticker impact
Tempus AI announced an extension of its data license agreement with Recursion, committing $42M in payments through 2029.
Potential modest upside for TEM as the deal secures future cash flow.
The agreement locks in multi-year fees, but the amount is modest relative to market cap.
Recursion Pharmaceuticals granted Tempus a non‑exclusive worldwide license to its RNA sequencing model “TxFM”.
Likely neutral to slightly positive for RXRX as the deal adds a new revenue stream.
The license expands market reach but the financial terms are not disclosed.
Market effects
Strengthens the AI‑driven precision‑medicine sector by showcasing collaborative licensing models.
May boost investor interest in US biotech and AI‑focused healthcare firms.
Highlights growing cross‑border AI partnerships in drug discovery.
Counterpoint
The modest $42M commitment may be insufficient to materially move the stock, and the deal could be a distraction from core product milestones.
Key entities
- CompanyTempus AI
US‑listed AI‑driven precision‑medicine firm (ticker TEM).
- CompanyRecursion Pharmaceuticals
US‑listed biotech developing AI platforms for drug discovery (ticker RXRX).
